FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Platinum Resistant Ovarian Cancer
Interventions
DRUG

Fosbretabulin tromethamine

CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.

DRUG

Placebo

Saline for infusion

Trial Locations (40)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

The Western Pennsylvania Hospital, Pittsburgh

18103

Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering, Allentown

21202

Mercy Medical Center; The Institute for Cancer Care, Baltimore

29303

Gibbs Cancer Center & Research Institute Spartanburg Medical Center, Spartanburg

30912

Augusta University, Augusta

33136

Sylvester Comprehensive Cancer Center University of Miami, Miami

33176

Baptist Health Medical Group Oncology, LLC, Miami

33612

Moffitt Cancer Center, Tampa

35249

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

36604

Mitchell Cancer Institute - USA Health System, Mobile

44718

Gabrail Cancer Center, Canton

45147

Universitätsklinikum Essen (AöR) Klinik für Frauenheilkunde und Geburtshilfe, Essen

64132

HCA Midwest Division - Sarah Cannon Cancer Institute, Kansas City

72076

Universitäts-Frauenklinik Dept. für Frauengesundheit, Tübingen

73104

Oklahoma Heath Sciences Center - Stephenson Cancer Center, Oklahoma City

74146

Tulsa Cancer Institute, Tulsa

75235

Dallas County Hospital District d/b/a Parkland Health and Hospital System, Dallas

Simmons Comprehensive Cancer Center; UT Southwestern Medical Center, Dallas

75246

Texas Oncology, P.A., Dallas

75702

Texas Oncology, P.A., Tyler

76022

Texas Oncology, Bedford

77380

Texas Oncology, P.A., The Woodlands

78229

Texas Oncology San Antonio, San Antonio

78731

Texas Oncology, P.A., Austin

80228

Rocky Mountain Cancer Centers, LLP, Lakewood

85016

Arizona Oncology Associates, PC - HAL, Phoenix

85711

Arizona Oncology Associates, PC - HOPE, Tucson

85724

University of Arizona Cancer Center, Tucson

90262

Oncology Institute of Hope and Innovation, Lynwood

92868

University of California Irvine, Orange

93105

Sansum Clinic, Santa Barbara

94115

California Pacific Medical Center, Research Institute, San Francisco

97239

OHSU Center for Women's Health & Knight Cancer Institute, Portland

97477

Willamette Valley Cancer Institute, Springfield

06102

Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering, Hartford

06904

Stamford Hospital - Bennett Cancer Center, Stamford

04074

Maine Medical Center, Scarborough

Unknown

UZ Leuven, Leuven

D-91054

Universitätsklinikum Erlangen, Erlangen

Sponsors
All Listed Sponsors
lead

Mateon Therapeutics

INDUSTRY